Synthesis and structure-activity relationships of 2-(1,4′-bipiperidin-1′-yl)thiazolopyridine as H3 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 21, 2009, Pages 6176-6180

  Rao, Ashwin U ^a   Palani, Anandan ^a   Chen, Xiao ^a   Huang, Ying ^a   Aslanian, Robert G ^a   West Jr , Robert E ^a   Williams, Shirley M ^a   Wu, Ren Long ^a   Hwa, Joyce ^a   Sondey, Christopher ^a   Lachowicz, Jean ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

2 (1,4 Bipiperidin 1 yl)thiazolopyridine; H3; Histamine

Indexed keywords

2 (1,4' BIPIPERIDIN 1' YL)THIAZOLOPYRIDINE; HISTAMINE H3 RECEPTOR ANTAGONIST; POTASSIUM CHANNEL HERG; PYRIDINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EX VIVO STUDY; IN VITRO STUDY; MOUSE; NONHUMAN; RAT; RECEPTOR OCCUPANCY; STRUCTURE ACTIVITY RELATION;

ANIMALS; HAPLORHINI; HISTAMINE ANTAGONISTS; HUMANS; MICE; MICE, INBRED ICR; MICROSOMES, LIVER; PYRIDINES; RATS; RECEPTORS, HISTAMINE H3; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATORS;

EID: 71749119385     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.09.006     Document Type: Article

References (44)

1. Hough L.B. Mol. Pharmacol. 59 (2001) 415-419
2. Arrang J.M., Garbarg M., and Schwartz J.C. Nature 302 (1983) 832-837
3. Schlicker E., Malinowska B., Kathmann M., and Gothert M. Fundam. Clin. Pharmacol. 8 (1994) 128-137
4. Clapham J., and Kilpatrick G.J. Br. J. Pharmacol. 107 (1992) 919-923
5. Esbenshade T.A., Fox G.B., and Cowart M.D. Mol. Interventions 6 (2006) 77-88
6. Leurs R., Blandina P., Tedford C., and Timmerman H. Trends. Pharmacol. Sci. 19 (1998) 177-183
7. Stark H., Schlicker E., and Schunack W. Drugs Future 21 (1996) 507-520
8. Gemkow M.J., Davenport A.J., Harich S., Ellenbroek B.A., Cesura A., and Hallett D. Drug Discovery Today 14 (2009) 509-515
9. Oades R.D. Prog. Neurobiol. 29 (1987) 365-391
10. Monti J.M. Life Sci. 53 (1993) 1331-1338
11. Vohora D., Pal S.N., and Pillai K.K. Pharmacol. Biochem. Behav. 68 (2001) 735-741
12. Velligan D.I., and Miller A.L. J. Clin. Psychiatry 60 (1999) 25-28
13. Hancock A.A. Curr. Opin. Invest. Drugs 4 (2003) 1190-1197
14. Hancock A.A., Bush E.N., Jacobson P.B., Faghih R., and Esbenshade T.A. Inflamm. Res. 53 (2004) S47-S48
15. Malmlof K., Hastrup S., Schellerup W.B., Hansen B., Peschke B., Jeppesen C., Hohlweg R., and Rimvall K. Biochem. Pharmacol. 73 (2007) 1237
16. Lovenberg T.W., Roland B.L., Wilson S.J., Jiang X., Pyati J., Hurvar A., Jackson M.R., and Erlander M.G. Mol. Pharmacol. 55 (1999) 1101-1107
17. Leurs R., Bakker R.A., Timmerman H., and de Esch I.J.P. Nat. Rev. Drug Disc. 4 (2005) 107-120
18. Celanire S., Wijtmans M., Talaga P., Leurs R., and de Esch I.J.P. Drug Discovery Today 10 (2005) 1613-1627
19. Stark H., Kathmann M., Schlicker E., Schunack W., Schlegel B., and Wolfgang S. Mini-Rev. Med. Chem. (2004) 965-977
20. Lin J., and Lu A.Y.H. Clin. Pharmacokinet. 35 (1998) 361-390
21. Zhang M., Ballard M.E., Pan P., Roberts S., Faghih R., Cowart M.D., Esbenshade T.A., Fox G.B., Decker M.W., Hancock A.A., and Rueter L.E. Brain Res. 1045 (2005) 142-149
22. Cowart M.D., Altenbach R., Black L., Faghih R., Zhao C., and Hancock A.A. Mini-Rev. Med. Chem. (2004) 979-992
23. Cowart M.D., Faghih R., Curtis M.P., Gfesser G.A., Bennani Y.L., Black L.A., Pan L., Marsh K.C., Sullivan J.P., Esbenshade T.A., Fox G.B., and Hancock A.A. J. Med. Chem. 48 (2005) 38-55
24. Esbenshade T.A., Fox G.B., Krueger K.M., Miller T.R., Kang C.H., Denny L.I., Witte D.G., Yao B.B., Pan L., Wetter J., Marsh K., Bennani Y.L., Cowart M.D., Sullivan J.P., and Hancock A.A. J. Pharmacol. Exp. Ther. 313 (2005) 165-175
25. Fox G.B., Esbenshade T.A., Pan J.B., Radek R.J., Krueger K.M., Yao B.B., Browman K.E., Buckley M.J., Ballard M.E., Komater V.A., Miner H., Zhang M., Faghih R., Rueter L.E., Bitner R.S., Drescher K.U., Wetter J., Marsh K., Lemaire M., Porsolt R.D., Bennani Y., Sullivan J.P., Cowart M.D., Decker M.W., and Hancock A.A. J. Pharmacol. Exp. Ther. 313 (2005) 176-190
26. Medhurst A.D., Atkins A.R., Beresford I.J., Brackenborough K., Briggs M.A., Calver A.R., Cilia J., Cluderay J.E., Crook B., Davis J.B., Davis R.K., Davis R.P., Dawson L.A., Foley A.G., Gartlon J., Gonzalez M.I., Heslop T., Hirst W.D., Jennings C., Jones D.N.C., Lacroix L.P., Martyn A., Ociepka S., Ray A., Regan C.M., Roberts J.C., Schogger J., Southam E., Stean T.O., Trail B.K., Upton N., Wadsworth G., Wald J.A., White T., Witherington J., Woolley M.L., Worby A., and Wilson D.M. J. Pharmacol. Exp. Ther. 321 (2007) 1032-1045
27. Meier G., Apelt J., Reichert U., Grassman S., Ligneau X., Elz S., Leurquin F., Ganellin C.R., Schwartz J.-C., Schunack W., and Stark H. Eur. J. Pharmacol. Sci. 13 (2001) 249
28. Faghih R., Dwight W., Vasudevan A., Dinges J., Conner S.E., Esbenshade T.A., Bennani Y.L., and Hancock A.A. Bioorg. Med. Chem. Lett. 12 (2002) 3077
29. Apodaca R., Dvorak C.A., Xiao W., Barbier A.J., Boggs J.D., Wilson S.J., Lovenberg T.W., and Carruthers N.I. J. Med. Chem. 46 (2003) 3938
30. Walczyński K., Zuiderveld O.P., and Timmerman H. Eur. J. Med. Chem. 40 (2005) 15-23
31. Walczyński K., Guryn R., Zuiderveld O.P., and Timmerman H. Farmaco 54 (1999) 684-694
32. Walczyński K., Guryn R., Zuiderveld O.P., and Timmerman H. Archiv der Pharmazie 332 (1999) 389-398
33. Webrouck L., Megens A.A.H.P., Stokbroekx R.A., and Niemegeers C.J.E. Drug Dev. Res. 24 (1991) 41-51
34. Smith, R.; O'Connor, S. J.; Coish, P.; Lowe, D.; Clark, R. B.; Stebbins, J.; Campbell, A.-M.; Akuche, C.; Shelekhin, T. PCT Int. Appl. WO 2006044775.
35. Belyankin, A. V.; Duplantier, A. J.; Zhang, L.; O'Donnell, C. J.; Rogers, B. N.; Vincent, L. A.; Sviridov, S. I. PCT Int. Appl. WO 2006051410.
36. Okafor C.O. Tetrahedron 44 (1988) 1187-1194
37. i values were determined from curves fit to the data using GraphPad Prism nonlinear, least-squares, curve-fitting program.
38. Wagaw S., and Buchwald S.L. J. Org. Chem. 61 (1996) 7240-7241
39. Torraca K.E., Huang X., Parrish C.A., and Buchwald S.L. J. Am. Chem. Soc. 123 (2001) 10770-10771
40. Miyaura N., and Suzuki A. Chem. Rev. 95 (1995) 2457-2483
41. For the hERG IW protocol, see the following:. Sorota S., Zhang X.-S., Margulis M., Tucker K., and Priestley T. Assay Drug Dev. Technol. 3 (2005) 47-57
42. Black L.A., Liu H., Diaz G.J., Fox G.B., Browman K.E., Wetter J., Marsh K.C., Miller T.R., Esbenshade T.A., Brioni J., and Cowart M.D. Inflamm. Res. 57 (2008) S45-S46
43. 3H-N-α-methylhistamine and 10 μM thioperamide for non-specific binding or assay buffer for total binding. Incubations were performed in quadruplet and stopped by rapid filtration on a Brandel Harvester using Unifilter-96, GF/B plates presoaked in 0.3% PEI for 30 min. The remaining radioactivity was measured on a Packard TopCount-NTX. Specific binding was calculated by subtracting the non-specific binding from the total.
44. -5 M N-α-methylhistamine over this time. cAMP assays were performed with an AlphaScreen cAMP assay kit.